Novavax heads into the back half of August with one of the most persistent short positions in US biotech — and a borrow market that just shifted gears in a way worth watching.
Short interest is the defining feature of this stock right now. At 28.1% of the free float, NVAX carries a short burden that ranks near the very bottom of the universe — a short score of 81.6 out of 100 confirms its place among the most pressured names in the market. That position has been building, not shrinking: short shares rose roughly 2% on the week and are up more than 2.5% on the month, reaching approximately 45.7 million shares as of August 18. The bears are not covering.
The more interesting development is in the lending market. Availability had been extremely tight through most of early August — dropping below 5% on several sessions between August 3 and August 6, meaning nearly every share in the lending pool was already out on loan. That squeeze has since eased sharply. Availability climbed back to 33.9% by August 18, a level more consistent with late July conditions, and is up more than 400% on the week. The cost to borrow, meanwhile, has drifted lower — running at 0.83% against a month-ago level closer to 1.1%. The combination of more available supply and lower borrowing cost tells a specific story: demand for new short positions is not accelerating, even as the aggregate short count rises. The new shorts are getting in at more comfortable terms than their predecessors.
Options positioning offers no clear directional lean. The put/call ratio is running at 0.56, essentially in line with its 20-day average of 0.57 and carrying a near-zero z-score. That places it squarely in the middle of the past year's range — well below the 0.73 annual high and above the 0.38 low. Options traders are neither reaching for downside protection nor piling into calls. Given the magnitude of short interest, the absence of a defensive bid in options is at least mildly notable.
The Street is divided, with bulls holding the louder megaphone on price targets. The mean analyst target of $14.00 implies roughly 77% upside from the current $7.93 — though the most recent analyst action of substance dates to June, when BTIG reiterated its Buy with a $19 target. TD Cowen sits at Hold with a $9 target, barely above the current price. JP Morgan, which cut its Underweight target to $6 last November, remains the most bearish voice in the room. The bull case centers on the Sanofi partnership, clinical differentiation through lower reactogenicity, and a vaccine pipeline with broader addressable indications. Bears point to ongoing cash burn, a heavily negative book value (P/B of -2.2), a deeply negative EPS yield, and competition from better-capitalized peers. One genuine positive: EPS momentum factor scores rank in the 94th-96th percentile over both 30- and 90-day windows, suggesting estimate revisions have been running in the right direction even if the company remains loss-making.
Institutional flows add a layer of texture. BlackRock added nearly 1.2 million shares in its most recent filing (through July 31), and State Street added over 2.7 million. Those are meaningful accumulations relative to the float for a stock trading below $8. Coatue opened a fresh position of 3.8 million shares as of March 31 — a high-profile entry from a firm not known for passive index-matching. Sanofi itself holds a 4.2% stake unchanged, a reminder that the partnership is more than contractual. On the insider front, all recent filings are zero-value awards to directors, with no open-market buying or selling since the CFO sold a small tranche in March.
The most recent earnings print, delivered August 6, produced a one-day move of +3.2% and a five-day follow-through of +5.7% — the stock rewarded rather than punished buyers after the release. The next event is pencilled in for November 6. Between now and then, the key variable is whether the partial easing in borrow availability proves durable or reverts. Availability spiking above 90% — the level seen in early August — would signal renewed pressure on the lending pool and a more aggressive short rebuild worth watching.
See the live data behind this article on ORTEX.
Open NVAX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
